GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: example 57 [US11466000B2]
Compound class:
Synthetic organic
Comment: Enozertinib is the INN for an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is claimed in Voronoi Inc. patent US11466000B2 (as example 57) [1]. Voronoi have two EGFR inhibitors listed on their development pipeline page (VRN07 and VRN11), but without a name to structure declaration we cannot be sure which one wil be aligned with this INN.
|
|
References |
1. Lee Y H, Kang JH, Kang SI, Ko YK, Ko EH, Choi HG, Son JB, Kim ND. (2022)
Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component. Patent number: US11466000B2. Assignee: Voronoi Inc. Priority date: 08/11/2021. Publication date: 11/10/2022. |